359 related articles for article (PubMed ID: 24728329)
1. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.
Schiff MH; Jaffe JS; Freundlich B
Ann Rheum Dis; 2014 Aug; 73(8):1549-51. PubMed ID: 24728329
[TBL] [Abstract][Full Text] [Related]
2. Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis.
Schiff MH; Sadowski P
Rheumatol Int; 2017 Feb; 37(2):213-218. PubMed ID: 28012023
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate.
Pichlmeier U; Heuer KU
Clin Exp Rheumatol; 2014; 32(4):563-71. PubMed ID: 24983446
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.
Braun J; Kästner P; Flaxenberg P; Währisch J; Hanke P; Demary W; von Hinüber U; Rockwitz K; Heitz W; Pichlmeier U; Guimbal-Schmolck C; Brandt A;
Arthritis Rheum; 2008 Jan; 58(1):73-81. PubMed ID: 18163521
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration.
Bianchi G; Caporali R; Todoerti M; Mattana P
Adv Ther; 2016 Mar; 33(3):369-78. PubMed ID: 26846283
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.
Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
J Rheumatol; 2004 Apr; 31(4):645-8. PubMed ID: 15088287
[TBL] [Abstract][Full Text] [Related]
7. Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study.
Branco JC; Barcelos A; de Araújo FP; Sequeira G; Cunha I; Patto JV; Oliveira M; Mateus MP; Couto M; Nero P; Pinto P; Monteiro P; Castelão W; Félix J; Ferreira D; Almeida J; Silva MJ
Adv Ther; 2016 Jan; 33(1):46-57. PubMed ID: 26724937
[TBL] [Abstract][Full Text] [Related]
8. Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?
Yadlapati S; Efthimiou P
Rheumatol Int; 2016 May; 36(5):627-33. PubMed ID: 26936262
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R
Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941
[TBL] [Abstract][Full Text] [Related]
10. Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice.
Li CKH; Baker K; Jones T; Coulson E; Roberts A; Birrell F
Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1306-1311. PubMed ID: 32475009
[TBL] [Abstract][Full Text] [Related]
11. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.
Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
J Rheumatol; 2006 Mar; 33(3):481-5. PubMed ID: 16463431
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
13. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
Zhuang Y; Xu Z; Frederick B; de Vries DE; Ford JA; Keen M; Doyle MK; Petty KJ; Davis HM; Zhou H
Clin Ther; 2012 Jan; 34(1):77-90. PubMed ID: 22169051
[TBL] [Abstract][Full Text] [Related]
14. Nearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations.
Freundlich B; Kivitz A; Jaffe JS
J Clin Rheumatol; 2014 Aug; 20(5):256-60. PubMed ID: 25036562
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
16. Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review.
Goodman SM; Cronstein BN; Bykerk VP
Clin Exp Rheumatol; 2015; 33(2):272-8. PubMed ID: 25536122
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis.
Islam MS; Haq SA; Islam MN; Azad AK; Islam MA; Barua R; Hasan MM; Mahmood M; Safiuddin M; Rahman MM; Osmany MF; Bari N; Rumki RS; Rashid FB
Mymensingh Med J; 2013 Jul; 22(3):483-8. PubMed ID: 23982537
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
Genovese MC; Tena CP; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Delaet I; Teng J; Alten R
J Rheumatol; 2014 Apr; 41(4):629-39. PubMed ID: 24584926
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Subcutaneous Methotrexate in Chronic Plaque Psoriasis.
Yesudian PD; Leman J; Balasubramaniam P; Macfarlane AW; Al-Niaimi F; Griffiths CE; Burden AD; Warren RB
J Drugs Dermatol; 2016 Mar; 15(3):345-9. PubMed ID: 26954320
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis.
Tuková J; Chládek J; Nemcová D; Chládková J; Dolezalová P
Clin Exp Rheumatol; 2009; 27(6):1047-53. PubMed ID: 20149329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]